应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
未开盘 02-27 16:08:22
4.520
-0.710
-13.58%
最高
6.150
最低
4.230
成交量
527.70万
今开
5.300
昨收
5.230
日振幅
36.71%
总市值
23.26亿
流通市值
23.26亿
总股本
5.15亿
成交额
2,625万
换手率
1.03%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
百济神州预计2025年实现经营利润为正 创新药企回暖在即?
21世纪经济报道 · 02-27 23:15
百济神州预计2025年实现经营利润为正 创新药企回暖在即?
福安药业:公司目前没有接入AI智能创新药领域
互动易 · 02-27 12:51
福安药业:公司目前没有接入AI智能创新药领域
众生药业最新公告:控股子公司众生睿创获得一类创新药RAY1225注射液III期临床试验伦理批件
证券之星 · 02-27 10:00
众生药业最新公告:控股子公司众生睿创获得一类创新药RAY1225注射液III期临床试验伦理批件
【众生药业:控股子公司获得一类创新药RAY1225注射液III期临床试验伦理批件】金融界2月27日消息,近日,众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,属于长效GLP-1类药物,具有双重激动活性,可调节人体代谢和控制血糖。本次III期临床试验组长单位伦理批件的获得,标志着该试验将全面启动。该注射液获得伦理批件对公司短期财务状况和经营业绩不构成重大影响,但临床试验存在风险和不确定性,公司将按规定履行信息披露义务。
金融界 · 02-27 09:56
【众生药业:控股子公司获得一类创新药RAY1225注射液III期临床试验伦理批件】金融界2月27日消息,近日,众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,属于长效GLP-1类药物,具有双重激动活性,可调节人体代谢和控制血糖。本次III期临床试验组长单位伦理批件的获得,标志着该试验将全面启动。该注射液获得伦理批件对公司短期财务状况和经营业绩不构成重大影响,但临床试验存在风险和不确定性,公司将按规定履行信息披露义务。
荣昌生物:2024年亏损14.68亿元
美港电讯 · 02-27 08:14
荣昌生物:2024年亏损14.68亿元
【荣昌生物:2024年亏损14.68亿元】荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。
金融界 · 02-27 08:14
【荣昌生物:2024年亏损14.68亿元】荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。
两份重磅征求意见稿被热传,创新药定价要有更大空间了吗?
美港电讯 · 02-27 02:54
两份重磅征求意见稿被热传,创新药定价要有更大空间了吗?
永泰生物-B盘中异动 股价大涨5.16%
市场透视 · 02-27 01:32
永泰生物-B盘中异动 股价大涨5.16%
科伦博泰生物股价创新高 业界人士:企业盈利改善、资本信心回暖有望形成正向带动
美港电讯 · 02-26 12:37
科伦博泰生物股价创新高 业界人士:企业盈利改善、资本信心回暖有望形成正向带动
2月26日海南海药涨停分析:CAR-T疗法,化学原料药,创新药概念热股
证券之星 · 02-26 07:17
2月26日海南海药涨停分析:CAR-T疗法,化学原料药,创新药概念热股
A股收评:沪指涨1.02% 中国银河、中金公司尾盘涨停
美港电讯 · 02-26 07:04
A股收评:沪指涨1.02% 中国银河、中金公司尾盘涨停
港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复(附概念股)
智通财经 · 02-26 05:53
港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复(附概念股)
【创新药板块大幅走高 君实生物等多股涨超10%】百济神州涨近4%,创历史新高,君实生物、博瑞医药、益方生物涨超10%,诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上,据统计,2024年全年创新药企License-out交易首付款总额(31.6亿美元)甚至超过了创新药研发融资的总额(27.1亿美元),创新药出海成为国内创新药企核心动力。
金融界 · 02-26 05:41
【创新药板块大幅走高 君实生物等多股涨超10%】百济神州涨近4%,创历史新高,君实生物、博瑞医药、益方生物涨超10%,诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上,据统计,2024年全年创新药企License-out交易首付款总额(31.6亿美元)甚至超过了创新药研发融资的总额(27.1亿美元),创新药出海成为国内创新药企核心动力。
永泰生物-B盘中异动 快速上涨6.94%
市场透视 · 02-26 01:48
永泰生物-B盘中异动 快速上涨6.94%
金凯生科:公司已关注到人工智能技术在创新药行业领域的应用
证券之星 · 02-25 13:00
金凯生科:公司已关注到人工智能技术在创新药行业领域的应用
去年和复星医药“分手”!这家创新药企要再冲IPO!但亏损依旧……
市场资讯 · 02-25 11:15
去年和复星医药“分手”!这家创新药企要再冲IPO!但亏损依旧……
富士莱:甲磺酸阿帕替尼是创新药,目前还在专利期内
证券之星 · 02-25 09:00
富士莱:甲磺酸阿帕替尼是创新药,目前还在专利期内
华海药业:公司已在创新药早期研发阶段中应用AI技术
证券之星 · 02-25 08:00
华海药业:公司已在创新药早期研发阶段中应用AI技术
科兴制药与百诚医药签署出海战略合作协议
美港电讯 · 02-25 04:33
科兴制药与百诚医药签署出海战略合作协议
【科兴制药与百诚医药签署出海战略合作协议】近日,科兴制药与杭州百诚医药科技股份有限公司(“百诚医药”)全资子公司浙江玖盈科技有限公司达成出海战略合作,签约仪式于2月24日在深圳成功举办。两家企业有机会在创新药研发、海外商业化等多个领域,建立深层次、多元化战略合作关系。
金融界 · 02-25 04:10
【科兴制药与百诚医药签署出海战略合作协议】近日,科兴制药与杭州百诚医药科技股份有限公司(“百诚医药”)全资子公司浙江玖盈科技有限公司达成出海战略合作,签约仪式于2月24日在深圳成功举办。两家企业有机会在创新药研发、海外商业化等多个领域,建立深层次、多元化战略合作关系。
加载更多
公司概况
公司名称:
永泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":4.52,"timestamp":1740643702035,"preClose":5.23,"halted":0,"volume":5277000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.6932816124729743,"marketStatus":"未开盘","change":-0.71,"latestTime":"02-27 16:08:22","open":5.3,"high":6.15,"low":4.23,"amount":26252420,"amplitude":0.367113,"askPrice":4.52,"askSize":1000,"bidPrice":4.4,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.6402758438972794,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1740706200000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.23,"openAndCloseTimeList":[[1740619800000,1740628800000],[1740632400000,1740643200000]],"volumeRatio":2.5984833562871925,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2514354636","title":"百济神州预计2025年实现经营利润为正 创新药企回暖在即?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514354636","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514354636?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:15","pubTimestamp":1740698127,"startTime":"0","endTime":"0","summary":"【百济神州预计2025年实现经营利润为正 创新药企回暖在即?】2月27日晚间,百济神州发布了2024年第四季度及全年的财务业绩,同时发布A股业绩快报公告。财报显示,百济神州2024年在全球市场持续展示出强劲的增长势头,全年总收入达38亿美元,同比增长55%。产品收入成为推动营收增长的主要动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202502283332138871.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202502283332138871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LU2328871848.SGD","159992","688235","LU0588546209.SGD","LU1969619763.USD","BK1574","BK1583","ONC","06978","LU0307460666.USD","BK4139","BK1588","BK1161","BK0239","06160","BK1500"],"gpt_icon":0},{"id":"2514385097","title":"福安药业:公司目前没有接入AI智能创新药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385097","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385097?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:51","pubTimestamp":1740660660,"startTime":"0","endTime":"0","summary":"有投资者向福安药业提问, 公司是否接入AI智能创新药?公司回答表示,您好,公司目前没有接入AI智能创新药领域,谢谢!\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-27/doc-inemxvsi0692951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","300194","BK1574","BK1161","BK0239","BK0132","BK0028","159992","159819","06978"],"gpt_icon":0},{"id":"2514799968","title":"众生药业最新公告:控股子公司众生睿创获得一类创新药RAY1225注射液III期临床试验伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514799968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514799968?lang=zh_cn&edition=full","pubTime":"2025-02-27 18:00","pubTimestamp":1740650442,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得伦理审查批件,批准项目开展。RAY1225注射液属于长效GLP-1类药物,有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。该药物的III期临床试验将全面启动,但存在研发项目推进及研发效果不达预期的风险,未来产品市场竞争格局也存在不确定性。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700033251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1141","002317","BK0188","BK0077","BK1574","BK1161","BK1576","BK1583","03347","06978"],"gpt_icon":0},{"id":"2514798938","title":"【众生药业:控股子公司获得一类创新药RAY1225注射液III期临床试验伦理批件】金融界2月27日消息,近日,众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,属于长效GLP-1类药物,具有双重激动活性,可调节人体代谢和控制血糖。本次III期临床试验组长单位伦理批件的获得,标志着该试验将全面启动。该注射液获得伦理批件对公司短期财务状况和经营业绩不构成重大影响,但临床试验存在风险和不确定性,公司将按规定履行信息披露义务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514798938","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514798938?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:56","pubTimestamp":1740650165,"startTime":"0","endTime":"0","summary":"金融界2月27日消息,近日,众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件,批准项目开展。本次III期临床试验组长单位伦理批件的获得,标志着该试验将全面启动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175648431102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK1141","002317","BK1574","159992","06978","BK1576","GLP","BK1583","BK0239","BK4144","BK4134","BK4590","BK1161","III","BK0077","03347"],"gpt_icon":0},{"id":"2514741821","title":"荣昌生物:2024年亏损14.68亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514741821","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514741821?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:14","pubTimestamp":1740644099,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","LU1064130708.USD","BK1574","LU2328871848.SGD","BK1161","159992","LU1064131003.USD","688331","06978","LU1969619763.USD","LU2148510915.USD","09995","BK1583"],"gpt_icon":0},{"id":"2514821223","title":"【荣昌生物:2024年亏损14.68亿元】荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514821223","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514821223?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:14","pubTimestamp":1740644053,"startTime":"0","endTime":"0","summary":"荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27161448426178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09995","06978","688331","159992"],"gpt_icon":0},{"id":"2514129428","title":"两份重磅征求意见稿被热传,创新药定价要有更大空间了吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514129428","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514129428?lang=zh_cn&edition=full","pubTime":"2025-02-27 10:54","pubTimestamp":1740624869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2514881659","title":"永泰生物-B盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514881659","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514881659?lang=zh_cn&edition=full","pubTime":"2025-02-27 09:32","pubTimestamp":1740619934,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时32分,永泰生物-B股票出现波动,股价急速拉升5.16%。永泰生物-B股票所在的生物技术行业中,整体跌幅为0.79%。其相关个股中,科笛-B、创胜集团-B、永泰生物-B涨幅较大,振幅较大的相关个股有科笛-B、腾盛博药-B、永泰生物-B,振幅分别为7.42%、5.96%、5.74%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022709321498942fda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022709321498942fda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2514346428","title":"科伦博泰生物股价创新高 业界人士:企业盈利改善、资本信心回暖有望形成正向带动","url":"https://stock-news.laohu8.com/highlight/detail?id=2514346428","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514346428?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:37","pubTimestamp":1740573431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","HSCEI","07226","YANG","159992","BK1161","06978","HSTECH"],"gpt_icon":0},{"id":"2514001121","title":"2月26日海南海药涨停分析:CAR-T疗法,化学原料药,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514001121?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:17","pubTimestamp":1740554256,"startTime":"0","endTime":"0","summary":"证券之星消息,海南海药2月26日涨停收盘,收盘价5.31元。该股于9点40分涨停,未打开涨停,截止收盘封单资金为3739.58万元,占其流通市值0.6%。2月26日的资金流向数据方面,主力资金净流入9608.11万元,占总成交额37.45%,游资资金净流出4558.29万元,占总成交额17.77%,散户资金净流出5049.82万元,占总成交额19.68%。近5日资金流向一览见下表:该股为CAR-T疗法,化学原料药,创新药概念热股,当日CAR-T疗法概念上涨1.82%,化学原料药概念上涨1.63%,创新药概念上涨1.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600021106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000566","BK1161","BK0239","BK1574","06978","159992","BK0060","BK0146","BK0070","BK0188"],"gpt_icon":0},{"id":"2514009588","title":"A股收评:沪指涨1.02% 中国银河、中金公司尾盘涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009588","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514009588?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:04","pubTimestamp":1740553440,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["161027","BK0224","BK1161","BK0212","159992","BK1148","003021","BK1501","BK1564","600126","399300","399006","BK0185","399001","03908","BK0188","159796","BK0071","06881","BK0044","BK0077","159982","BK0276","BK1574","SG9999002828.SGD","06978","601881","601995","BK1147","BK1516","09979","BK0102","000932"],"gpt_icon":0},{"id":"2514900875","title":"港股概念追踪|百济神州成为国内“创新药一哥” 机构看好创新药2025年估值修复(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514900875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514900875?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:53","pubTimestamp":1740549201,"startTime":"0","endTime":"0","summary":"2月21日,百济神州以27亿元市值差距超越恒瑞医药,成为“创新药一哥”。百济神州的创新药收入增长迅猛,其BTK抑制剂泽布替尼全球销售额突出。百济神州市值新高有业绩支撑,预计2025年全年经营利润为正。国金证券发布研究报告称,建议继续贯彻AI医药+创新药2025年医药投资两大布局主线。该行表示,看好行业估值修复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","LU0307460666.USD","LU2488822045.USD","06160","BK1589","06978","IE00B5MMRT66.SGD","BK1161","LU1794554557.SGD","BK4139","YANG","BK1500","IE00BPRC5H50.USD","ONC","BK1583","HSTECH","BK1574","01801","BK1588","LU0588546209.SGD","LU1720050803.USD","LU1969619763.USD","LU0417516571.SGD","09926","LU0348784397.USD","LU0348783233.USD","159992","BK0239","HSCEI","IE00B543WZ88.USD","LU2328871848.SGD"],"gpt_icon":1},{"id":"2514070291","title":"【创新药板块大幅走高 君实生物等多股涨超10%】百济神州涨近4%,创历史新高,君实生物、博瑞医药、益方生物涨超10%,诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上,据统计,2024年全年创新药企License-out交易首付款总额(31.6亿美元)甚至超过了创新药研发融资的总额(27.1亿美元),创新药出海成为国内创新药企核心动力。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070291","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514070291?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:41","pubTimestamp":1740548461,"startTime":"0","endTime":"0","summary":"百济神州涨近4%,创历史新高,君实生物、博瑞医药、益方生物涨超10%,诺诚健华、新诺威、荣昌生物、昭衍新药等多股涨逾5%。消息面上,据统计,2024年全年创新药企License-out交易首付款总额(31.6亿美元)甚至超过了创新药研发融资的总额(27.1亿美元),创新药出海成为国内创新药企核心动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26134148395945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688235","300765","688331","09995","688428","LU1969619763.USD","ONC","688382","09969","603127","BK1500","LU0307460666.USD","06978","688180","LU2328871848.SGD","LU0588546209.SGD","LU1064130708.USD","LU1064131003.USD","BK1574","BK1515","BK1161","LU2148510915.USD","BK1141","06127","BK0216","BK4139","BK0226","159992","BK1588","BK1576","01877","06160","688166","BK0239","BK1583"],"gpt_icon":0},{"id":"2514020965","title":"永泰生物-B盘中异动 快速上涨6.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514020965?lang=zh_cn&edition=full","pubTime":"2025-02-26 09:48","pubTimestamp":1740534490,"startTime":"0","endTime":"0","summary":"2025年02月26日早盘09时48分,永泰生物-B股票出现波动,股价急速上涨6.94%。永泰生物-B股票所在的生物技术行业中,整体涨幅为0.03%。其相关个股中,科济药业-B、创胜集团-B、来凯医药-B涨幅较大,振幅较大的相关个股有科济药业-B、创胜集团-B、来凯医药-B,振幅分别为16.91%、14.71%、13.25%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260948119892d820&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260948119892d820&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2514957099","title":"金凯生科:公司已关注到人工智能技术在创新药行业领域的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2514957099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514957099?lang=zh_cn&edition=full","pubTime":"2025-02-25 21:00","pubTimestamp":1740488437,"startTime":"0","endTime":"0","summary":"证券之星消息,金凯生科02月25日在投资者关系平台上答复投资者关心的问题。有计划在研发中应用人工智能技术吗?公司已关注到人工智能技术在创新药行业领域的应用,作为服务于创新药企的CDMO企业,公司希望能够跟上行业新技术运用步伐、通过积极探索和尝试来运用新技术提质增效。但截至目前,相关技术尚未在公司有实质性应用,这里也提请您注意相关投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500039615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","301509","161631","159992","06978","BK0239","BK1574"],"gpt_icon":0},{"id":"2514067150","title":"去年和复星医药“分手”!这家创新药企要再冲IPO!但亏损依旧……","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067150","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514067150?lang=zh_cn&edition=full","pubTime":"2025-02-25 19:15","pubTimestamp":1740482100,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 时隔两年半,真实生物科技有限公司再次向港交所申请主板上市。 此前,真实生物的产品阿兹夫定于2022年7月附条件获批,成为首款获批上市的国产新冠肺炎口服药物。 紧接着,获批十天后,真实生物于2022年8月4日首次向港交所递交了招股书,引发市场巨大关注。但是,真实生物的首次赴港路却以失败告终。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-02-25/doc-inemtccz1114606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK0060","BK0183","BK0188","BK0012","BK0239","600196","BK1515","BK1191","BK0028","BK0175","BK0196","BK1161","BK0187","02196","BK0096","06978","BK1574","BK1593"],"gpt_icon":0},{"id":"2514068554","title":"富士莱:甲磺酸阿帕替尼是创新药,目前还在专利期内","url":"https://stock-news.laohu8.com/highlight/detail?id=2514068554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514068554?lang=zh_cn&edition=full","pubTime":"2025-02-25 17:00","pubTimestamp":1740474025,"startTime":"0","endTime":"0","summary":"证券之星消息,富士莱(301258)02月25日在投资者关系平台上答复投资者关心的问题。投资者:甲磺酸阿帕替尼原料药对应的药物是中国首个自主研发的靶向抗癌创新药。请问公司的审批通过的甲磺酸阿帕替尼原料药属于创新药原料吗?富士莱董秘:尊敬的投资者,您好!甲磺酸阿帕替尼是创新药,目前还在专利期内。谢谢!以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500029555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06978","159992","BK1574","301258","BK1161"],"gpt_icon":0},{"id":"2514541510","title":"华海药业:公司已在创新药早期研发阶段中应用AI技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2514541510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514541510?lang=zh_cn&edition=full","pubTime":"2025-02-25 16:00","pubTimestamp":1740470414,"startTime":"0","endTime":"0","summary":"证券之星消息,华海药业(600521)02月25日在投资者关系平台上答复投资者关心的问题。投资者:请问公司是否有计划使用ai技术帮助药物的研发,谢谢!华海药业董秘:您好,感谢您对公司的关注和支持!公司高度重视AI技术对药物研发的推动作用。目前,公司已在创新药早期研发阶段中应用AI技术,包括:靶点发现与验证、化合物筛选与设计环节等。此外,公司也在积极推进DeepSeek本地化部署,以进一步提升研发效率,同时继续探索AI技术在研发、临床、生产等各场景的应用。谢谢!以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500026088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","BK0201","159992","BK0012","600521","06978","BK0070","BK1161","BK1574","BK0239","BK0028"],"gpt_icon":0},{"id":"2514535039","title":"科兴制药与百诚医药签署出海战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2514535039","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514535039?lang=zh_cn&edition=full","pubTime":"2025-02-25 12:33","pubTimestamp":1740458018,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688136","301096","159992","BK1574","BK1161","06978","BK0239","BK0216"],"gpt_icon":0},{"id":"2514036149","title":"【科兴制药与百诚医药签署出海战略合作协议】近日,科兴制药与杭州百诚医药科技股份有限公司(“百诚医药”)全资子公司浙江玖盈科技有限公司达成出海战略合作,签约仪式于2月24日在深圳成功举办。两家企业有机会在创新药研发、海外商业化等多个领域,建立深层次、多元化战略合作关系。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514036149","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514036149?lang=zh_cn&edition=full","pubTime":"2025-02-25 12:10","pubTimestamp":1740456642,"startTime":"0","endTime":"0","summary":"近日,科兴制药与杭州百诚医药科技股份有限公司(“百诚医药”)全资子公司浙江玖盈科技有限公司达成出海战略合作,签约仪式于2月24日在深圳成功举办。两家企业有机会在创新药研发、海外商业化等多个领域,建立深层次、多元化战略合作关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25121048364370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","BK1161","BK0239","688136","06978","BK1574","301096","159992"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.3951},{"period":"1month","weight":0.6496},{"period":"3month","weight":1.0926},{"period":"6month","weight":0.5322},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.9652}],"compareEarnings":[{"period":"1week","weight":0.0506},{"period":"1month","weight":0.1727},{"period":"3month","weight":0.2211},{"period":"6month","weight":0.3185},{"period":"1year","weight":0.4343},{"period":"ytd","weight":0.1824}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.213686},{"month":3,"riseRate":0.25,"avgChangeRate":-0.117615},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077145},{"month":5,"riseRate":0.5,"avgChangeRate":0.017788},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.2","shortVersion":"4.31.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}